Abstract
The presence of hypertension among the population with human immunodeficiency virus (HIV) has become a new threat to the health and well-being of people living with this disease, in particular, among those who received antiretroviral therapy. The estimated prevalence of high blood pressure in HIV‐infected patients is significantly higher than the rate observed in HIV‐uninfected subjects. The approach to the HIV-positive patient requires the assessment of individual cardiovascular risk and its consideration when designing the individualized target. On the other hand, the numerous pharmacological interactions of antiretroviral (ARV) drugs are essential elements to take into account. Serum levels of any kind of antihypertensive drugs may be influenced by the coadministration of protease inhibitors, non-nucleoside reverse transcriptase inhibitor, or other antiretroviral. Similarly, plasma concentrations of antiretroviral drugs can be increased by the concomitant use of calcium channel blockers or diuretics. In this regard, the treatment of high blood pressure in HIV patients should be preferentially based on ACE inhibitors or thiazide/thiazide-like diuretics or their combination.
Keywords: Antiretroviral, hypertension, antihypertensive treatment, HIV infection, interactions, cardiovascular disease.
Current Pharmaceutical Design
Title:Antiretroviral Treatment and Antihypertensive Therapy
Volume: 27 Issue: 40
Author(s): Nicolás R. Robles*, Francesco Fici, Julian Valladares and Guido Grassi
Affiliation:
- Servicio de Nefrologia, Hospital Universitario de Badajoz, Badajoz,Spain
Keywords: Antiretroviral, hypertension, antihypertensive treatment, HIV infection, interactions, cardiovascular disease.
Abstract: The presence of hypertension among the population with human immunodeficiency virus (HIV) has become a new threat to the health and well-being of people living with this disease, in particular, among those who received antiretroviral therapy. The estimated prevalence of high blood pressure in HIV‐infected patients is significantly higher than the rate observed in HIV‐uninfected subjects. The approach to the HIV-positive patient requires the assessment of individual cardiovascular risk and its consideration when designing the individualized target. On the other hand, the numerous pharmacological interactions of antiretroviral (ARV) drugs are essential elements to take into account. Serum levels of any kind of antihypertensive drugs may be influenced by the coadministration of protease inhibitors, non-nucleoside reverse transcriptase inhibitor, or other antiretroviral. Similarly, plasma concentrations of antiretroviral drugs can be increased by the concomitant use of calcium channel blockers or diuretics. In this regard, the treatment of high blood pressure in HIV patients should be preferentially based on ACE inhibitors or thiazide/thiazide-like diuretics or their combination.
Export Options
About this article
Cite this article as:
Robles R. Nicolás*, Fici Francesco , Valladares Julian and Grassi Guido, Antiretroviral Treatment and Antihypertensive Therapy, Current Pharmaceutical Design 2021; 27 (40) . https://dx.doi.org/10.2174/1381612827666210810090805
DOI https://dx.doi.org/10.2174/1381612827666210810090805 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17
Current Alzheimer Research Implantable Microfluidic Device: An Epoch of Technology
Current Pharmaceutical Design The Future of Diabetes Management by Healthy Probiotic Microorganisms
Current Diabetes Reviews Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) New Frontiers in Cystic Fibrosis Therapy: The Case of Stem Cells
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Avocado (Persea americana) Seed as a Source of Bioactive Phytochemicals
Current Pharmaceutical Design Effect of a New Class of Compounds of the Group of Substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the Inflammatory and Cytokine Response in Experimental Myocardial Infarction
Current Vascular Pharmacology Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Current Vascular Pharmacology Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Mitochondrial Injury and Targeted Intervention in Septic Cardiomyopathy
Current Pharmaceutical Design Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology Current Patents on Osteoinductive Molecules for Bone Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry